Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
about
Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancerDirect integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis.Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments.MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerGene co-expression modules as clinically relevant hallmarks of breast cancer diversity.Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus.The role of S6K1 in ER-positive breast cancer.Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.Microarray Meta-Analysis and Cross-Platform Normalization: Integrative Genomics for Robust Biomarker DiscoveryOn the role of autophagy in human diseases: a gender perspective.mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy.Everolimus: targeted therapy on the horizon for the treatment of breast cancer.Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.Breast cancer tissue slices as a model for evaluation of response to rapamycin.PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer.
P2860
Q27001170-F974912B-F84D-4D78-A3A3-A4E017DFB8F4Q30558563-8E8CDA12-D3C6-4FE1-9412-BB551BB6DCDDQ33683126-814313BC-3B2A-47EB-9027-C9F9AA645851Q34048134-399EE99E-7CB1-49B3-8175-9649C2886E9DQ34088518-0B0CD86B-28E4-4AFF-B56C-348DD836808BQ34405157-85309617-5CEB-4E1F-8489-F365E08E5E65Q34542434-359B4AAD-9EE3-47E8-8A7E-9389E860AE9EQ35091690-17C044A9-DE6A-4189-8379-75A43269FC13Q36191321-7661DAD4-41F3-4D5A-8685-821B36B97735Q36304094-E0B669C0-CC5E-4F04-AC44-E5CFA7E2B03BQ37072929-22670AB0-1446-4D8E-AF03-CC93BDE0C1FDQ37200781-EECF43D4-4829-4839-89E3-CE07A6E047C2Q37295450-0B86279B-5BFE-4466-872A-482F8889B927Q37863123-57FCF5FD-0E87-41D0-AD5C-CD1D2EDA0B5DQ37998418-4F354C14-BAA8-470C-BC0B-227AD81F5597Q38105361-DECD4F9B-D46C-4F1E-8208-FEA986E65B4AQ38490536-556CDA4E-6E0D-4338-A51E-EF646273E5ABQ55001013-8D874CB8-F08C-4B5B-8A0A-3E04BF32337E
P2860
Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Gene expression profiling of r ...... ceptor-positive breast cancer.
@en
Gene expression profiling of r ...... ceptor-positive breast cancer.
@nl
type
label
Gene expression profiling of r ...... ceptor-positive breast cancer.
@en
Gene expression profiling of r ...... ceptor-positive breast cancer.
@nl
prefLabel
Gene expression profiling of r ...... ceptor-positive breast cancer.
@en
Gene expression profiling of r ...... ceptor-positive breast cancer.
@nl
P2093
P2860
P1476
Gene expression profiling of r ...... ceptor-positive breast cancer.
@en
P2093
E Jane Macaskill
J Michael Dixon
Jeremy S Thomas
John M S Bartlett
Lorna Renshaw
Vicky S Sabine
P2860
P2888
P304
P356
10.1007/S10549-010-0928-6
P407
P577
2010-05-18T00:00:00Z
P5875
P6179
1044708499